AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine

Laboratorios AstraZeneca, anuncia la disponibilidad de una vacuna contra SARS COV 2, a partir de adenovirus recombinante, para el mes de septiembre del 2020.

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine
— Leer en www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html